Immunotherapy Products
Immunitor is a small biotech company and has been in the forefront leader in the global development, clinical trials, studies, regulatory registrations, and all other research commercialization initiatives for all Immunitor oral pill vaccine products.
Immunitor had registered numerous clinical trials and studies with US FDA and Health Protection Branch, Health Canada, and had received approval for two Orphan Drug designations from USA FDA (V5 and V7). These products have helped countless people worldwide to overcome health challenges, and address various unmet medical needs in cancer and infectious disease treatment and prevention.
Immunotherapy products developed and marketed by Immunitor offers new hope in the treatment of hard-to-treat cancer and infectious diseases. Leading Immunitor products are clinically tested in many countries, and are found to be:
V5 to optimize liver health and for potential treatment of liver diseases including, cancer:
V5 is developed and tested for the treatment of liver cancer. In some patients (but not all), patients with late stage liver cancer had been known to be treated with V5 resulting in complete remission and or significant reduction/shrinkage of cancer with prolonged survival.
Immunitor V5 has demonstrated unparalleled success in all clinical studies to date for the treatment of liver cancer, which is predominantly hepatocellular carcinoma (HCC). Immunitor studies report that patients taking just one oral Immunitor V5 immunotherapeutic vaccine tablet daily exhibited an industry unprecedented 12-month response and survival rate in 90% of cases. This dramatically exceeds the less than 10% average survival of HCC patients on conventional anticancer drugs.
​
HAP-V+ and HAP-VL to support the recovery/treatment of COVID-19:
HAP-V+ is a patented oral pill vaccine to support strong immunity, as this is the obvious natural defense to catching colds and/or viral infections, HAP-V+ is today increasingly being used in countries where it is currently available in cases of COVID-19.
In some of these countries where both supplement and/or treatment options are very limited, people with COVID-19 have been resorting to the Immunitor supplement, many later advising that within days of taking HAP-V+, they began to feel better. This supports the extensive anecdotal use reports of people feeling better within as little as 24 hours when taking HAP-V+ on the first evidence of cold or flu.
As reported earlier this year, preliminary tests conducted by a leading Asian university research institute on the Immunitor HAP-V+ Supplement have shown safety and a 90% reduction on SARS-CoV-2 virus infectivity in mammalian cells following exposure to HAP-V+. This laboratory testing highlights HAP-V+ methodology and its potential to inactivate and/or prevent viral infection, and its oral mucosal administration advantage.
Whilst all supplement use feedback and early laboratory results continue to be encouraging, to progress regulatory approval for HAP-V+ as a treatment for COVID-19, influenza, and other respiratory conditions, will still require substantial validation through clinical trials.
Anxiety, depression, can't sleep (insomnia)? V7 can help!
V7 consists of inactivated non-pathogenic strain of Mycobacterium vaccae, which may affect the brain in a similar way to antidepressants.
​
Anxiety, depression, insomnia, emotional distress and other psychological conditions are a major public health crisis today. The COVID-19 pandemic further heightens the prevalence and seriousness of this crisis. Anti-depressants and other psychological medications are common therapeutic solutions to address issue. However, the over dependence on anti-depression drugs can lead to long term side effects such as sexual problems, addiction, suicidal, weight gain and other serious ill effects. As a result, there is a compelling need to develop a chemical-free, more natural therapeutic approach to combat anxiety, depression and suicidal tendency that are devoid of these long term side effects of anti-depressants.
Mycobacterium vaccae is a harmless bacterium found in soil and experimental studies have shown that this bacterium can act as natural antidepressant in animals and humans. These studies suggest Mycobacterium vaccae can increase the release of serotonin levels in the body, and its effects can mirror on the brain neurons that mimic Prozac and other anti-depression medications.
V7 is an innovative product developed by Immunitor and its consists of completely inactivated non-pathogenic strain of Mycobacterium vaccae. Originally developed and proven effective to treat tuberculosis, V7 is an US FDA orphan designated drug, it is currently marketed in many countries as health supplement to support and to promote robust mental health conditions, and helps to combat depression, anxiety and insomnia. V7 users often experienced better quality sleep, overall emotional well being and less anxiety and none have reported any short term to long term side effects.
Dove has a strong partnership with Immunitor to promote V7 as a chemical-free therapeutic solution that clearly can address this unmet medical need and addressing this major public health crisis that is often forgotten due to the current COVID-19 crisis.
​
An University of Colorado, Boulder-led study showing that injecting beneficial Mycobacterium vaccae into mice can make them more resilient to stress has been named among the “top 10 advancements and breakthroughs” of 2016 by the nation’s leading non-governmental funder of mental health research.
Now, lead author Christopher Lowry, an associate professor in the Department of Integrative Physiology, is moving forward with clinical trials to see if altering the microbiome, or composition of resident bacteria, in military veterans with posttraumatic stress disorder can be beneficial.
​
V3
V3-Myom is based on dehydrated proteins collected from inactivated blood and tumor tissues of patients with uterine myoma. The vaccine is expected to trigger a specific anti-cancer immune response and anti-inflammatory effect.
“Immunitor strives to help women who often have no treatment options and our preliminary investigations have shown very promising results.”
Manuka Honey
Manuka honey is made in Australia and New Zealand by bees that pollinate the native leptospermum scoparium bush (also known as a tea tree).
Dostarlimab
"This clinical trial was published by a team of 32 researchers on June 5, 2022, in one of the most prestigious medical journals New England Journal of Medicine."